Serious diseases do not discriminate; they affect people from all walks of life and in all economic circumstances. For that reason, Genzyme recognises that our responsibility to the patient community does not end with simply developing effective therapies.
We are also committed to helping those therapies reach patients, regardless of their ability to pay, through an International Charitable Access Program (ICAP). In Australia, ICAP has been offered as a bridge to reimbursement allowing patients to access treatment prior to government subsidisation.
For more information on Genzyme’s ICAP program and the status of certain programs, please contact Medical Information.
Through the LSDP, the Australian Government provides subsidised access, for eligible patients, to expensive life saving drugs for very rare life-threatening conditions.
On 9 April 2014, the Minister for Health, the Hon Peter Dutton MP, announced that the post-market review of the Life Saving Drugs Programme (LSDP Review) would proceed. Since that time, the LSDP has been under post-market review.
Access to medicines in New Zealand is provided through the Pharmaceutical Management Agency, PHARMAC. Medicines may be provided through the Pharmaceutical Schedule or through the Named Patient Pharmaceutical Access scheme.